Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & EMBASE  
     Home | Subscribe | Feedback  

SYMPOSIUM
[Download PDF
 
Year : 2004  |  Volume : 50  |  Issue : 1  |  Page : 30-34  

Malaria parasite interactions with the human host

DS Pouniotis, O Proudfoot, G Minigo, JL Hanley, M Plebanski 
 Vaccine Development and Infectious Diseases Unit, The Austin Research Institute, Austin Campus, Heidelberg, Victoria 3084, Australia

Correspondence Address:
M Plebanski
Vaccine Development and Infectious Diseases Unit, The Austin Research Institute, Austin Campus, Heidelberg, Victoria 3084
Australia

Abstract

The interaction between the malaria parasite and the human host involves a number of interactions that result in the parasite evading the human immune system. Since the stages of the malaria lifecycle are complex, this allows the use of various immune evasion strategies by the malaria parasite and has major implications in the development of a vaccine for malaria endemic areas. The present review highlights key host:parasite interactions. Plasmodia puts selection pressure on human gene frequencies, and studies into host genetic factors such as the Duffy blood group and sickle cell anaemia offer insight into the host- parasite relationship. In addition, parasite interactions with the different effector arms of the immune system can result in altered peptide ligand (APL) antagonism which alters the immune response from a pro- to an anti-inflammatory T cell response. Recent insights into the interaction between professional antigen presenting cells, dendritic cells (DCs), and malaria parasites is discussed in detail.



How to cite this article:
Pouniotis D S, Proudfoot O, Minigo G, Hanley J L, Plebanski M. Malaria parasite interactions with the human host.J Postgrad Med 2004;50:30-34


How to cite this URL:
Pouniotis D S, Proudfoot O, Minigo G, Hanley J L, Plebanski M. Malaria parasite interactions with the human host. J Postgrad Med [serial online] 2004 [cited 2019 Jun 26 ];50:30-34
Available from: http://www.jpgmonline.com/text.asp?2004/50/1/30/6650


Full Text

The malaria parasite is a prevalent human pathogen with at least 300 million acute cases of malaria each year globally and more than a million deaths. A deeper understanding of the nature and regulation of protective immune mechanisms against this parasite will facilitate the development of much needed vaccines. Persistence of the asexual erythrocytic (blood) stages following natural recovery from the acute phase of the infection is common in malaria infections.[1] An important reason for the persistence of malaria infections within populations is the ability of the parasites to undergo repeated antigenic variation.[2],[3] However, during the acute, and to a lesser extent the chronic phase of blood stage infection, there is also significant suppression of the immune response to heterologous antigens,[4],[5],[6] as well as general immunosuppression, such as impairment of antigen presenting cell (APC) function.[7] There is evidence of the suppression and evasion of parasite-specific responses during acute malaria: mechanisms which include clonal antigenic variation and altered peptide ligand (APL) antagonism.[3] Despite extensive efforts in vaccine development and design, there is still no effective vaccine available for use in malaria endemic areas. Rodent models have largely facilitated the understanding of the effects of blood stage malaria infection on the development of immune responses. Considered collectively, studies to date indicate that generating protective immunity via vaccination is a realistic goal, but also pose questions about host: parasite immune inter-phase.

The malaria parasite has a complex lifecycle, involving humans and Anopheles mosquitoes [Figure:1]. The human stages develop after an infected female Anopheles mosquito injects sporozoites (10 to 100 during the blood meal) into the human.[8],[9] These migrate to the liver (within 30 minutes), where those not blocked by antibodies penetrate into the liver, and begin dividing within hepatocytes.[10] During this time, cytotoxic T cells (CTLs) and IFN gamma-producing cells can promote elimination of intracellular parasites. This replication lasts from 2-10 days, and merozoites develop within hepatocytes. These cells then rupture, and merozoites enter the blood and invade erythrocytes. Each hepatocyte releases tens of thousands of merozoites.[11] These events comprise the pre-erythrocytic (liver) stage of malaria. After merozoites have invaded host erythrocytes they mature and continue to divide asexually to become schizonts, rupturing 48 hours later.[12] Each intraerythrocytic expansion-burst-infection cycle results in 20-30 new merozoites.[12] Murine strains of malaria complete pre and intraerythrocytic development faster than human strains, and produce less merozoites per schizont. Rodent malaria models indicate blood-stage protection can be antibody-mediated, but IFN gamma production and T cell proliferation in response to blood-stage antigens are also associated with protection.[13] A sexual form of blood stage parasite is responsible for the infection of the salivary glands of new mosquito vectors.

 Parasite / host genetic interactions



In addition to host-driven genetic selection acting on malaria parasite populations, Plasmodium exerts selection pressure on human gene frequencies. Where malaria is endemic, it is reasonable to assume that infection contributes positively to the allele frequency of variants associated with protection. The first such alleles identified affect the RBC structure or function. The gene conferring the Duffy blood group is the most striking example; people of this blood type are completely immune to Plasmodium vivax blood stage infection, as they lack the relevant receptor on RBC membranes.[14] Sickle cell anaemia allele, severely deleterious in the homozygote, is associated with malaria protection in the heterozygote, possibly due to abnormal RBC shape. Along with RBC-related genes, various genes affecting components of the immune system have been associated with protection from malaria. Inducible nitric oxide synthase 2 (iNOS2) is an enzyme that modulates nitric oxide (NO) production, ultimately affecting malarial immunity. Protective variant alleles associated with high NO production have been identified in multiple African populations.[15],[16] Fc gamma receptor II (Fc gamma RII) facilitates monocyte binding to the IgG subclasses. A polymorphism restricting the affinity of Fc gamma RII to IgG1 and IgG3 has been investigated in Western Kenyans, and correlates with P. falciparum immunity.[17] Severe malaria, which can lead to neurological sequelae and death may involve CD36-mediated sequestration of parasitised erythrocytes.[18] Heterozygosity for an allelic variant of CD36 is associated with protection from severe malaria in Africans. Importantly, MHC Class I B53 (MHC-B53), and II DQB1FNx010501 and DRB1FNx011302 alleles are associated with protective clinical responses in African populations.[19],[20] MHC-B53 is very common in African populations and presumably, this association has contributed to the high frequency observed in these populations.

 Parasite interaction



Altered Peptide Ligand (APL) antagonism

Natural immunity to malaria takes years to acquire, at least partly due to a very effective immune evasion strategy mediated by naturally occurring variants of the same antigenic epitopes, capable of inhibiting memory T cells [Figure:2]. This so-called ′altered peptide ligand′ (APL) antagonism affects specific cell lysis and lymphocyte proliferation, as well as cytokine production. Naturally exposed individuals have cytotoxic T lymphocytes (CTLs) specific for pre-erythrocytic stage antigens, and CD4 T cells as well as antibodies specific for both erythrocytic and pre-erythrocytic stage antigens.[11],[20],[21],[22],[23],[24] The most abundant protein on the sporozoite coat is the circumsporozoite (CS) protein, which participates in the parasites binding to the liver cells. Antibodies against CS protein can block liver cell infection in vivo[25],[26] and in vitro.[27] CTLs against CS protein alone can confer complete protection in mice[26],[27] suggesting that it is an important target for generating liver stage immunity. In addition to B cell and CTL epitopes, the CS protein also contains CD4 T cell epitopes and thus could theoretically induce a broad range of effector mechanisms.

Many of the T cell epitopes in the CS protein are polymorphic, with the immuno-dominant CD4 T cell epitope of CS (Th2R, aa 326-347) containing the most known sequence variability.[22] Fourteen variants have been observed,[28] with 9 co-existing in The Gambia.[28],[29] Interestingly, the same variants can be found in widely different geographical regions, which may represent a convergent evolution.[28],[30],[31],[32] Two naturally occurring APL variants of this epitope have been shown to inhibit proliferation and IFN gamma production from T cells reactive to the index (vaccine) variant.[33] The mechanism of this antagonism appears two-fold. One APL variant is able to promote a switch towards IL-10 production when co-presented on the same or a separate antigen presenting cell (APC) with the IFN gamma-inducing vaccine variant.[33] This IL-10 then switches off proliferation and IFN gamma production; these can be restored by neutralising IL-10 activity in vitro with monoclonal antibodies.[33] The other variant can similarly impair proliferation and IFN gamma production when co-presented on the same APC with the index variant, but is unable to do so if presented on a separate APC.[33] The mechanism of suppression by this second variant is still being investigated.

CS-specific CTL have been found only infrequently and at low levels in naturally exposed humans.[34] Moreover, 3 out of 4 known human CTL CS epitopes are polymorphic.[21] This observation stands in contrast to the CTL associated epitopes of other proteins present during the liver stage, many of which are highly conserved.[21] The two most polymorphic CS CTL epitopes are the ones found within the helper epitope regions TH2R and TH3R, and which we will call TC2R and TC3R. Most TC2R variants can bind HLA-A2 and some TC3R variants bind HLA-B35,[21] both of which are very common in West Africa, where P. falciparum malaria is endemic.[35] The two HLA-B35 binding natural variant epitopes have been found to be not only mutually antagonistic in vitro,[36] but also to be able to prevent the priming of specific memory T cells from naive precursors.[33] Preliminary studies suggest that the TC2R region will have similar potent APL antagonistic variants, although the pattern of distribution in the population is likely to be complex, given the large number of variants in this region. This potent antagonistic activity at two levels, memory/effector and naive/memory may explain why parasites bearing these antagonistic variants are found more frequently together (as co-infections) in West Africa, and more frequently in HLA-B35 individuals than in individuals with other HLA types.[36]

 Impairment of dendritic cell function



Dendritic cells (DC) are usually the first cells of the immune system to encounter foreign organisms. Their activation in the face of an infectious pathogen, and their subsequent interaction with other cells of the immune system is a major component of the immune response.[37] For example, Tascon et al (2000) showed that the interaction between Mycobacterium tuberculosis and a DC cell line (tsDC) results in an increase in surface expression of CD80 and CD86 and the secretion of cytokines in culture, such as IL-1 which promotes the pro-inflammatory activity of macrophages, and IL-12 which promotes Th1 type T cell differentiation and effector function.[38] This results in induction of antigen-specific Th1 CD4 cell responses capable of protecting mice against subsequent experimental tuberculosis challenge.[38] Some pathogens such as Leishmania major infect DCs directly; in this case the Langerhans cells that resident in the skin. Infected DCs migrate and present antigen to T cells in draining lymph nodes resulting in the activation of antigen-specific CD8 and CD4 T cells and immunity.[39],[40]

It is reasonable to assume that DCs also play a critical role in initiating immune responses to malaria. Urban et al (1999) first showed that P. falciparum infected erythrocytes could prevent up-regulation of MHC Class II and co-stimulatory molecules CD83 and CD86 on human DCs in response to liposaccharide (LPS). In addition to affecting maturation, this impeded their ability to induce antigen-specific primary and secondary T cell responses.[13],[41] CD36 and CD51 were identified as the receptors on DCs responsible for this inhibitory effect.[42] These same receptors were found to mediate the inhibitory effect of macrophage function by decreasing TNF alpha (TNFa) and IL-1 secretion during malaria infection.[43] It is interesting that these molecules are responsible for the recognition of apoptotic cells by phagocytic cells, which can also have suppressive effects on DC function and maturation.[44] Interaction of infected erythrocytes with DCs also results in decreased IL-12 secretion by DCs, which would otherwise promote adequate T cell effector proliferation and differentiation towards a Th1 phenotype. An increase in IL-10 is also observed during infection, which could potentially directly suppress the stimulatory function of DCs as well as promote the generation of anti-inflammatory suppressor T cells.[45],[46],[47]

Pioneering in vitro human studies provoked the generation of a number of animal models investigating the functions of DCs during malaria infection in vivo. There are, however, definite differences between murine and human DCs, and species of rodent malaria differ from Plasmodia species that infect humans. Although there are less than a handful published studies, there are already inconsistencies in the literature on the effect of DC function after interaction with malaria parasites. Seixas and colleagues reported that GM-CSF grown bone marrow derived DCs (BM-DCs) up-regulate surface expression of MHC II, CD40 and CD86 after exposure to P. chabaudi infected erythrocytes. Their ability to stimulate T cell responses was maintained, and increased production of TNFa, IL-12 and IFN gamma was evident.?[48] Luyendyk and colleagues focused on analysing splenic CD11b+ and CD11c+ DC subtypes after acute infection with P. yoelii infected mice. They found that MHC II and CD80 molecules were up-regulated, and levels of CD86 were maintained.[49] These studies are in direct contradiction to what is seen in human DC studies, and to a recent study in mice by Ocana-Morgner and colleagues, who showed that GM-CSF grown BM-DCs and parasitised erythrocytes from P. yoelii inhibit DC maturation in vitro.[50] Thus, there is disagreement in the literature on the role of DCs in protective immunity to blood-stage malaria. Since the Plasmodia parasites have been shown to impair human[41],[50] and murine DC maturation[50] in vitro, it has been suggested that DCs do not prime protective immunity during infection. However, a recent publication by Bruna-Romero and colleagues showed that DCs presenting P. yoelii artificial (recombinant) sporozoite antigens can induce protective immunity against liver-stage malaria in mice and stimulate CD8 and CD4 T cell responses.[51] Our laboratory has addressed directly the hypothesis that DCs can prime blood-stage malaria immunity, and found that this is possible despite potential impaired maturation (Pouniotis, In Press) as measured by impaired up-regulation of co-stimulatory molecules and specific inhibition of CD8 antigen-specific responses (Pouniotis et al, submitted).

 Host-parasite interactions and implications for malaria vaccine development



Presently there is no malaria vaccine available to travellers or individuals living in malaria endemic areas. A recent promising vaccine to undergo clinical trials in Africa is the P. falciparum CS protein construct with recombinant hepatitis particles (RTS,S). Previously, this vaccine induced 50-60% pre-erythrocytic protection against homologous P.falciparum challenge in naïve volunteers.[52],[53] However, in Gambian adults, this vaccine did not induce similar patterns of immunity and protection was short-lived.[54],[55] It could be argued that this vaccine, targeting the highly polymorphic CS antigen, worked as expected, since a heterogenous population of parasites exist in endemic areas. McConkey and colleagues recently reported highly encouraging results on the induction of substantial P. falciparum specific CD4 and CD8 T cell levels in naive humans using Prime-boost.[56] Such protocols, if combined with high selectivity in antigen and variant/conserved epitope inclusion, may help overcome the problems of variant-specific immune evasion. Indeed, the most potent vaccine for malaria endemic areas may prove to be a multi-antigen, multi-stage combination. Recent malaria vaccine candidates tested in field trials are summarised in [Table:1].

However, identification of new and conserved antigens alone may not be sufficient for a vaccine that is successful in malaria endemic areas, as acute malaria infection is associated with T cell immunosuppression with a variety of generalised immunological changes, some of which are discussed above. An additional problem common to all vaccines is that in the field, they may preferentially re-stimulate pre-existing immunity induced by past infection with a bias towards a specific, and not necessarily protective, cytokine secretion pattern. It is hoped that as new vaccine approaches and understanding of the mechanisms of immune evasion at the host: parasite interphase progress, elements of its design will provide an effective vaccine for use in malaria endemic populations.

References

1Kremsner PG, Zotter GM, Feldmeier H, Graninger W, Rocha RM, Jansen-Rosseck R, et al. Immune response in patients during and after Plasmodium falciparum infection. J Infect Dis 1990;161:1025-8.
2Newbold CI. Antigenic variation in Plasmodium falciparum:mechanisms and consequences. Curr Opin Microbiol 1999;2:420-5.
3Plebanski M, Proudfoot O, Pouniotis D, Coppel RL, Apostolopoulos V, Flannery G. Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations. J Clin Invest 2002;110:295-301.
4Harbarth S, Meyer M, Grau GE, Loutan L, Ricou B. Septic Shock due to Cytomegalovirus Infection in Acute Respiratory Distress Syndrome after Falciparum Malaria. J Travel Med 1997;4:148-9.
5Theander TG, Svenson M, Bygbjerg IC, Kharazmi A, Jepsen S, Andersen BJ, et al. Inhibition of human lymphocyte proliferative response by serum from Plasmodium falciparum infected patients. Acta Pathol Microbiol Immunol Scand [C] 1987;95:257-63.
6Kalyesubula I, Musoke-Mudido P, Marum L, Bagenda D, Aceng E, Ndugwa C, et al. Effects of malaria infection in human immunodeficiency virus type 1-infected Ugandan children. Pediatr Infect Dis J 1997;16:876-81.
7Pulendran B, Palucka K, Banchereau J. Sensing pathogens and tuning immune responses. Science 2001;293:253-6.
8Rosenberg R, Wirtz RA, Schneider I, Burge R. An estimation of the number of malaria sporozoites ejected by a feeding mosquito. Trans R Soc Trop Med Hyg 1990;84:209-12.
9Ponnudurai T, Verhave JP, Meuwissen JH. Mosquito transmission of cultured Plasmodium falciparum. Trans R Soc Trop Med Hyg 1982;76:278-9.
10Ferreira MU, Kimura EA, Katzin AM, Santos-Neto LL, Ferrari JO, Villalobos JM, et al. The IgG-subclass distribution of naturally acquired antibodies to Plasmodium falciparum, in relation to malaria exposure and severity. Ann Trop Med Parasitol 1998;92:245-56.
11Nardin EH, Nussenzweig RS. T cell responses to pre-erythrocytic stages of malaria:role in protection and vaccine development against pre-erythrocytic stages. Annu Rev Immunol 1993;11:687-727.
12Nardin EH, Nussenzweig V, Nussenzweig RS, Collins WE, Harinasuta KT, Tapchaisri P, et al. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J Exp Med 1982;156:20-30.
13Good MF, Doolan DL. Immune effector mechanisms in malaria. Curr Opin Immunol 1999;11:412-9.
14Tamasauskas D, Powell V, Saksela K, Yazdanbakhsh K. A homologous naturally occurring mutation in Duffy and CCR5 leading to reduced receptor expression. Blood 2001;97:3651-4.
15Kun JF, Mordmuller B, Perkins DJ, May J, Mercereau-Puijalon O, Alpers M, et al. Nitric oxide synthase 2(Lambarene) (G-954C), increased nitric oxide production, and protection against malaria. J Infect Dis 2001;184:330-6.
16Hobbs MR, Udhayakumar V, Levesque MC, Booth J, Roberts JM, Tkachuk AN, et al. A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children. Lancet 2002;360:1468-75.
17Shi YP, Nahlen BL, Kariuki S, Urdahl KB, McElroy PD, Roberts JM, et al. Fcgamma receptor IIa (CD32) polymorphism is associated with protection of infants against high-density Plasmodium falciparum infection. VII. Asembo Bay Cohort Project. J Infect Dis 2001;184:107-11.
18Imbert P, Gerardin P, Rogier C, Ka AS, Jouvencel P, Brousse V, et al. Severe falciparum malaria in children:a comparative study of 1990 and 2000 WHO criteria for clinical presentation, prognosis and intensive care in Dakar, Senegal. Trans R Soc Trop Med Hyg 2002;96:278-81.
19Hill AV, Elvin J, Willis AC, Aidoo M, Allsopp CE, Gotch FM, et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992;360:434-9.
20Hill AV. Malaria resistance genes:a natural selection. Trans R Soc Trop Med Hyg 1992;86:225-32.
21Aidoo M, Lalvani A, Allsopp CE, Plebanski M, Meisner SJ, Krausa P, et al. Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. Lancet 1995;345:1003-7.
22Good MF. T cells, T sites, and malaria immunity-further optimism for vaccine development. J Immunol. 1988;140:1715-6.
23Malik A, Egan JE, Houghten RA, Sadoff JC, Hoffman SL. Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci USA 1991;88:3300-4.
24Zevering Y, Khamboonruang C, Rungruengthanakit K, Tungviboonchai L, Ruengpipattanapan J, Bathurst I, et al. Life-spans of human T-cell responses to determinants from the circumsporozoite proteins of Plasmodium falciparum and Plasmodium vivax. Proc Natl Acad Sci USA 1994;91:6118-22.
25Nardin P. ["Help-or at least do no harm"]. Schweiz Monatsschr Zahnmed. 1993;103:135-7.
26Hoffman SL, Berzofsky JA, Isenbarger D, Zeltser E, Majarian WR, Gross M, et al. Immune response gene regulation of immunity to Plasmodium berghei sporozoites and circumsporozoite protein vaccines. Overcoming genetic restriction with whole organism and subunit vaccines. J Immunol 1989;142:3581-4.
27Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989;341:323-6.
28Lockyer MJ, Marsh K, Newbold CI. Wild isolates of Plasmodium falciparum show extensive polymorphism in T cell epitopes of the circumsporozoite protein. Mol Biochem Parasitol 1989;37:275-80.
29Conway DJ, Greenwood BM, McBride JS. The epidemiology of multiple-clone Plasmodium falciparum infections in Gambian patients. Parasitology 1991;103:1-6.
30Gupta S, Hill AV. Dynamic interactions in malaria: Host heterogeneity meets parasite polymorphism. Proc R Soc Lond B Biol Sci 1995;261:271-7.
31McCutchan TF, Lal AA, do Rosario V, Waters AP. Two types of sequence polymorphism in the circumsporozoite gene of Plasmodium falciparum. Mol Biochem Parasitol 1992;50:37-45.
32Qari SH, Collins WE, Lobel HO, Taylor F, Lal AA. A study of polymorphism in the circumsporozoite protein of human malaria parasites. Am J Trop Med Hyg 1994;50:45-51.
33Plebanski M, Flanagan KL, Lee EA, Reece WH, Hart K, Gelder C, et al. Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of Plasmodium falciparum. Immunity 1999;10:651-60.
34Doolan DL, Khamboonruang C, Beck HP, Houghten RA, Good MF. Cytotoxic T lymphocyte (CTL) low-responsiveness to the Plasmodium falciparum circumsporozoite protein in naturally-exposed endemic populations: Analysis of human CTL response to most known variants. Int Immunol 1993;5:37-46.
35Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, et al. Common west African HLA antigens are associated with protection from severe malaria. Nature 1991;352:595-600.
36Gilbert SC, Plebanski M, Gupta S, Morris J, Cox M, Aidoo M, et al. Association of malaria parasite population structure, HLA, and immunological antagonism. Science 1998;279:1173-7.
37Rescigno M, Borrow P. The host-pathogen interaction: New themes from dendritic cell biology. Cell 2001;106:267-70.
38Tascon RE, Soares CS, Ragno S, Stavropoulos E, Hirst EM, Colston MJ. Mycobacterium tuberculosis-activated dendritic cells induce protective immunity in mice. Immunology 2000;99:473-80.
39Moll H, Fuchs H, Blank C, Rollinghoff M. Langerhans cells transport Leishmania major from the infected skin to the draining lymph node for presentation to antigen-specific T cells. Eur J Immunol 1993;23:1595-601.
40Moll H, Flohe S, Blank C. Dendritic cells seclude Leishmania parasites that persist in cured mice-a role in the maintenance of T-cell memory? Adv Exp Med Biol 1995;378:507-9.
41Urban BC, Ferguson DJ, Pain A, Willcox N, Plebanski M, Austyn JM, et al. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature 1999;400:73-7.
42Urban BC, Willcox N, Roberts DJ. A role for CD36 in the regulation of dendritic cell function. Proc Natl Acad Sci USA 2001;98:8750-5.
43Schwarzer E, Turrini F, Ulliers D, Giribaldi G, Ginsburg H, Arese P. Impairment of macrophage functions after ingestion of Plasmodium falciparum-infected erythrocytes or isolated malarial pigment. J Exp Med 1992;176:1033-41.
44Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997;390:350-1.
45Haase C, Jorgensen TN, Michelsen BK. Both exogenous and endogenous interleukin-10 affects the maturation of bone-marrow-derived dendritic cells in vitro and strongly influences T-cell priming in vivo. Immunology 2002;107:489-99.
46McBride JM, Jung T, de Vries JE, Aversa G. IL-10 alters DC function via modulation of cell surface molecules resulting in impaired T-cell responses. Cell Immunol 2002;215:162-72.
47Steinbrink K, Graulich E, Kubsch S, Knop J, Enk AH. CD4 (+) and CD8 (+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002;99:2468-76.
48Seixas E, Cross C, Quin S, Langhorne J. Direct activation of dendritic cells by the malaria parasite, Plasmodium chabaudi chabaudi. Eur J Immunol 2001;31:2970-8
49Luyendyk J, Olivas OR, Ginger LA, Avery AC. Antigen-presenting cell function during Plasmodium yoelii infection. Infect Immun 2002;70:2941-9.
50Ocana-Morgner C, Mota MM, Rodriguez A. Malaria blood stage suppression of liver stage immunity by dendritic cells. J Exp Med 2003;197:143-51.
51Bruna-Romero O, Rodriguez A. Dendritic cells can initiate protective immune responses against malaria. Infect Immun 2001;69:5173-6.
52Stoute JA, Kester KE, Krzych U, Wellde BT, Hall T, White K, et al. Long-term efficacy and immune responses following immunization with the RTS, S malaria vaccine. J Infect Dis 1998;178:1139-44.
53Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997;336:86-91.
54Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 2001;183:640-7.
55Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: A randomised trial. Lancet 2001;358:1927-34.
56McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003;9:729-35.
57Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998;177:1664-73.
58Wang R, Epstein J, Baraceros FM, Gorak EJ, Charoenvit Y, Carucci DJ, et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci USA. 2001;98:10817-22.
59Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000;18:1893-901.
60Keitel WA, Kester KE, Atmar RL, White AC, Bond NH, Holland CA, et al. Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine 1999;18:531-9.
61Lee EA, Palmer DR, Flanagan KL, Reece WH, Odhiambo K, Marsh K, et al. Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect Immun 2002;70:1417-21.
62Lawrence G, Cheng QQ, Reed C, Taylor D, Stowers A, Cloonan N, et al. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine 2000;18:1925-31.
63Saul A, Lawrence G, Smillie A, Rzepczyk CM, Reed C, Taylor D, et al. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 1999;17:3145-59.
64Genton B, Al-Yaman F, Anders R, Saul A, Brown G, Pye D, et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 2000;18:2504-11.

 
Wednesday, June 26, 2019
 Site Map | Home | Contact Us | Feedback | Copyright  and disclaimer